These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31686549)

  • 1. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
    Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
    [No Abstract]   [Full Text] [Related]  

  • 2. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is CD47 an innate immune checkpoint for tumor evasion?
    Liu X; Kwon H; Li Z; Fu YX
    J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of small-molecule inhibitors targeting CD47.
    Yu WB; Ye ZH; Chen X; Shi JJ; Lu JJ
    Drug Discov Today; 2021 Feb; 26(2):561-568. PubMed ID: 33197622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRPα-based cancer therapy.
    Olaoba OT; Ayinde KS; Lateef OM; Akintubosun MO; Lawal KA; Adelusi TI
    Crit Rev Oncol Hematol; 2023 Apr; 184():103939. PubMed ID: 36774991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
    Lian S; Xie R; Ye Y; Lu Y; Cheng Y; Xie X; Li S; Jia L
    Sci Rep; 2019 Mar; 9(1):4532. PubMed ID: 30872703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
    Logtenberg MEW; Jansen JHM; Raaben M; Toebes M; Franke K; Brandsma AM; Matlung HL; Fauster A; Gomez-Eerland R; Bakker NAM; van der Schot S; Marijt KA; Verdoes M; Haanen JBAG; van den Berg JH; Neefjes J; van den Berg TK; Brummelkamp TR; Leusen JHW; Scheeren FA; Schumacher TN
    Nat Med; 2019 Apr; 25(4):612-619. PubMed ID: 30833751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
    Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD47-SIRPα Immune Checkpoint.
    Logtenberg MEW; Scheeren FA; Schumacher TN
    Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal.
    Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J
    Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081
    [No Abstract]   [Full Text] [Related]  

  • 19. The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.
    Zhuang Z; Zhou J; Qiu M; Li J; Lin Z; Yi H; Liu X; Huang C; Tang B; Liu B; Li X
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
    Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.